Philadelphia, USA-based Reunion Neuroscience, a company developing psychedelics for the treatment of mental health conditions, has announced the closing of a $103 million Series A financing.

US cancer drug developer Context Therapeutics (Nasdaq: CNTX) saw its share close up 27.3% at $1.75 yesterday, after it revealed it has entered into a securities purchase agreement with certain new and ...

Swiss pharma giant Novartis (NOVN VX) has entered into an agreement to acquire USA-based biotech start-up Mariana Oncology, which is focused on developing novel radioligand therapies (RLTs) to ...

Amgen (Nasdaq: AMGN) has reported better-than-expected first quarter 2024 results, with simultaneous news from its obesity pipeline lifting the firm’s stock price by almost 15%. For the first quarter, ...

Subsidies for Danish drugmaker giant Novo Nordisk’s diabetes drug Ozempic (semaglutide) will be restricted in its home country due to rising public spending on the blockbuster diabetes medicine, which ...

San Diego, USA-based clinical-stage cell and gene therapy company Poseida Therapeutics (Nasdaq: PSTX) saw its shares close up more than 20% at $2.92 yesterday, when it revealed a second ...

Danish diabetes giant Novo Nordisk (NOV: N) today reported financial results for the first quarter of 2024, noting that sales ...

Johnson & Johnson (NYSE: JNJ), Genmab (CPH: GMAB) and Ono Pharmaceutical (TYO: 4528) were among pharma's big spenders in M&A ...

Californian biotech Enlaza Therapeutics has raised $100 million in a series A financing led by J.P. Morgan Asset Management’s Private Capital division.

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, has appointed Ashley Nagle as chief business officer (CBO) with immediate effect as part of a broader ...

Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify and optimize novel macrocyclic peptides against targets ...

UK clinical-stage biotech Barinthus Biotherapeutics, formerly Vaccitech, today announced the appointment of Dr Leon Hooftman as chief medical officer (CMO).